Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Why we must fight concept of carer as killer

Further to Professor Pirmohamed's excellent and informative article on adverse drug reactions (Clinical, October 18) it may be of interest that to observe an ADR with an incidence of one in 100, the medicine must be tested in an average of 300 patients.

For an ADR with an incidence of one in 1,000, some 6,000 patients must be followed.

Given that it is likely to require the assessment of several incidences of an ADR to determine a causal relationship between a drug and the ADR, the importance of post-marketing surveillance via, for example, the yellow card scheme, becomes apparent.

Dr Jim Laughton

Head of Medical Affairs

Otsuka Pharmaceuticals

London W4

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say